Home Interviews Abliva’s CEO: We are the leading programme in mitochondrial disease

Interviews
News
Nyheter
Studio

Abliva’s CEO: We are the leading programme in mitochondrial disease

26 August, 2024

Abliva’s CEO: We are the leading programme in mitochondrial disease

26 August, 2024

Abliva is developing drugs for the treatment of mitochondrial diseases, and the company posted positive interim phase II data with its lead candidate KL1333 this summer. Abliva’s CEO Ellen Donnelly stopped by the BioStock Studio to discuss the results and how they impact Abliva’s development moving forward.

Watch the interview with Abliva’s CEO Ellen Donnelly below:

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.